MediWound Ltd. (NASDAQ:MDWD) traded up 8.5% during trading on Wednesday . The stock traded as high as $7.58 and last traded at $7.29, with a volume of 53,858 shares traded. The stock had previously closed at $6.72.

Several equities research analysts have commented on the company. Zacks Investment Research upgraded MediWound from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research note on Tuesday, July 12th. Brean Capital restated a “buy” rating on shares of MediWound in a research note on Saturday, April 23rd. Finally, Jefferies Group lowered their target price on MediWound from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, July 29th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $13.63.

The stock’s 50 day moving average price is $7.75 and its 200-day moving average price is $7.67. The company’s market capitalization is $159.29 million.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.11. The firm earned $3.36 million during the quarter, compared to analyst estimates of $0.45 million. During the same quarter last year, the company earned ($0.19) EPS. The company’s quarterly revenue was up 115.8% compared to the same quarter last year. Equities research analysts expect that MediWound Ltd. will post ($1.04) EPS for the current year.

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.